BTK inhibitors versus venetoclax as first- or second-line therapy in chronic lymphocytic leukemia/small lymphocytic lymphoma: A real-world evidence study Research Letter

   


Authors: Roeker, L. E.; Han, Y.; Teschemaker, A.; Mato, A. R.; Thompson, M. C.
Title: BTK inhibitors versus venetoclax as first- or second-line therapy in chronic lymphocytic leukemia/small lymphocytic lymphoma: A real-world evidence study
Keywords: adult; controlled study; human tissue; aged; major clinical study; drug efficacy; monotherapy; rituximab; follow up; letter; protein bcl 2; cohort analysis; retrospective study; monoclonal antibody; cd20 antigen; immunoglobulin heavy chain; drug combination; drug therapy; chronic lymphatic leukemia; disease exacerbation; adverse drug reaction; chronic lymphocytic leukemia; clinical outcome; second-line treatment; ofatumumab; drug comparison; propensity score; chemoimmunotherapy; small lymphocytic lymphoma; ibrutinib; human; male; female; obinutuzumab; venetoclax; ecog performance status; acalabrutinib; bruton tyrosine kinase inhibitor; zanubrutinib; real-world evidence
Journal Title: American Journal of Hematology
Volume: 100
Issue: 4
ISSN: 0361-8609
Publisher: John Wiley & Sons, Inc.  
Date Published: 2025-04-01
Start Page: 720
End Page: 723
Language: English
DOI: 10.1002/ajh.27639
PUBMED: 39960132
PROVIDER: scopus
PMCID: PMC11886488
DOI/URL:

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85219696263&doi=10.1002%2fajh.27639&partnerID=40&md5=62ac849b301340ba2e982f8c7fda59b2
Notes: Letter -- MSK Cancer Center Support Grant (P30 CA008748) acknowledged in PubMed and PDF -- MSK corresponding author is Lindsey Roeker -- Source: Scopus
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Anthony R Mato
    236 Mato
  2. Lindsey Elizabeth Roeker
    146 Roeker
  3. Meghan Caitlin Thompson
    58 Thompson
Related MSK Work